Clene Inc.
Key Metrics
Market Snapshot
About
Clene Inc. is a clinical-stage biopharmaceutical company developing nanotechnology-based therapeutics for neurodegenerative diseases. Based in Salt Lake City, Utah, the company's lead asset is CNM-Au8, a suspension of gold nanocrystals designed to improve cellular energetics and neuroprotection. Clene is advancing CNM-Au8 in clinical trials for amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson's disease, targeting mitochondrial dysfunction underlying these conditions. The company's nanomedicine platform aims to deliver therapeutic benefits through catalytic mechanisms rather than traditional pharmacology.